Baicalein induces functional hypoxia-inducible factor-1alpha and angiogenesis

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• The hypoxia-inducible factor (HIF) pathway regulates cellular responses to oxygen levels.
• Targeting HIF offers pharmacological strategies for disease treatment.
• HIF-1alpha degradation is primarily mediated by HIF-1alpha-specific prolyl-4 hydroxylases (PHDs).

Purpose of the Study:

• To identify small molecules that up-regulate the HIF pathway by inhibiting prolyl hydroxylation.
• To investigate the mechanism of action of identified inhibitors.
• To evaluate the proangiogenic potential of lead compounds.

Main Methods:

• In vitro high-throughput screening for PHD inhibitors.
• Biochemical assays to confirm enzyme inhibition and binding kinetics.
• Cell-based assays to assess HIF-1alpha stabilization and transcriptional activity.
• In vivo chick chorioallantoic membrane assay for angiogenesis assessment.

Main Results:

• Baicalein identified as a potent inhibitor of PHD2 and asparaginyl hydroxylation of HIF-1alpha.
• Inhibitory effects reversed by 2-oxoglutarate and iron(II), indicating active site binding.
• Baicalein suppressed HIF-1alpha ubiquitination, increasing HIF-1alpha levels and activating HIF-1-mediated transcription.
• Baicalein promoted new blood vessel formation in vivo.

Conclusions:

• Baicalein effectively up-regulates the HIF pathway by inhibiting PHDs.
• Baicalein exhibits proangiogenic properties.
• Baicalein holds therapeutic potential for treating ischemic diseases.